Autres langues DermTech, Inc.

Actions

DMTK

US24984K1051

Marché Fermé - Nasdaq Autres places de cotation 22:30:00 03/05/2024			Varia. 5j.	Varia. 1 janv.
0,629 ^USD	-0,06%		+4,29%	-64,06%

19/04	DERMTECH, INC. : Lake Street moins optimiste	ZM
19/04	DERMTECH, INC. : BTIG n'est plus positif	ZM

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

North American Morning Briefing : Stock Futures -2-	22/04
DermTech Explores Strategic Alternatives to Boost Shareholder Value, Lays Off 100 Employees in Restructuring Plan	18/04
DermTech to Explore Strategic Alternatives and Implement Restructuring Plan	18/04
DermTech to Explore Strategic Alternatives and Implement Restructuring Plan	18/04
DermTech Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	01/04
DermTech Presents Research Abstracts at the 2024 American Academy of Dermatology (AAD) Annual Meeting and New Research Published in the Journal of Investigative Dermatology	11/03
DermTech Presents Research Abstracts at the 2024 American Academy of Dermatology (AAD) Annual Meeting and New Research Published in the Journal of Investigative Dermatology	08/03
DermTech : 2023 Q4 Transcript	01/03
DermTech, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29/02
DermTech, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	29/02
Earnings Flash (DMTK) DERMTECH Reports Q4 Revenue $3.9M, vs. Street Est of $4.03M	29/02
DermTech Reports Fourth-Quarter 2023 Financial Results	29/02
DermTech Announces Release Date for Fourth-quarter 2023 Financial Results	13/02
DermTech Announces Additional Restructuring Actions to Focus on Revenue Growth and Streamline Operations	31/01
Dermtech, Inc. Announces Cessation of Claudia Ibarra as Chief Operating Officer	31/01
DermTech Announces Positive Topline Results From a Study Evaluating the DermTech Melanoma Test across All Skin Types	19/01
DermTech Announces Positive Topline Results From a Study Evaluating the DermTech Melanoma Test (DMT) Across All Skin Types	18/01
DermTech Announces Positive Topline Results from A Study Evaluating the Dermtech Melanoma Test Across All Skin Types	18/01
DERMTECH SIMPLIFIES THE DERMTECH MELANOMA TEST BY DISCONTINUING THE OPTIONAL TERT ADD-ON ASSAY	17/01
DermTech Simplifies the DermTech Melanoma Test (DMT) by Discontinuing the Optional TERT Add-on Assay	16/01

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues DermTech, Inc.

Actions

DMTK

US24984K1051

Autres langues

Filtres